COMPUGROUP MEDICAL SE & CO. KGAA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.52 EUR | +0.51% |
|
-2.89% | -27.39% |
| May. 13 | COMPUGROUP MEDICAL : Reduced to Neutral by Deutsche Bank | ZD |
| May. 09 | Berenberg rates Compugroup at 'Buy' - Target 46 euros | DP |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,065 | 4,224 | 3,746 | 1,879 | 1,980 | 1,435 | - | - |
| Enterprise Value (EV) 1 | 3,505 | 4,704 | 4,374 | 2,571 | 2,682 | 2,095 | 2,016 | 1,930 |
| P/E ratio | 42.8 x | 56.1 x | 54.7 x | 25.7 x | 43.1 x | 16.5 x | 13.3 x | 12 x |
| Yield | 0.78% | 0.64% | 0.7% | 1.39% | 2.64% | 2.64% | 2.74% | 2.9% |
| Capitalization / Revenue | 4.11 x | 5.04 x | 3.65 x | 1.66 x | 1.67 x | 1.16 x | 1.11 x | 1.05 x |
| EV / Revenue | 4.7 x | 5.62 x | 4.27 x | 2.28 x | 2.26 x | 1.69 x | 1.56 x | 1.42 x |
| EV / EBITDA | 19.7 x | 22.5 x | 20.5 x | 11.9 x | 11.7 x | 7.6 x | 6.78 x | 6.1 x |
| EV / FCF | 36.6 x | 49.6 x | 43.3 x | 37.3 x | 23.7 x | 24.9 x | 16.9 x | 16.2 x |
| FCF Yield | 2.73% | 2.02% | 2.31% | 2.68% | 4.21% | 4.01% | 5.9% | 6.15% |
| Price to Book | 11.9 x | 6.62 x | 6.08 x | 2.79 x | 2.96 x | 2.06 x | 1.91 x | 1.76 x |
| Nbr of stocks (in thousands) | 48,071 | 53,735 | 52,647 | 52,235 | 52,235 | 52,159 | - | - |
| Reference price 2 | 63.75 | 78.60 | 71.15 | 35.98 | 37.90 | 27.52 | 27.52 | 27.52 |
| Announcement Date | 2/5/20 | 2/4/21 | 3/10/22 | 2/9/23 | 2/7/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 746 | 837.3 | 1,025 | 1,130 | 1,188 | 1,237 | 1,292 | 1,362 |
| EBITDA 1 | 178 | 209 | 213.4 | 216.4 | 229.8 | 275.5 | 297.2 | 316.4 |
| EBIT 1 | 115.6 | 133.6 | 102.7 | 104 | 114 | 153.6 | 180.8 | 196.6 |
| Operating Margin | 15.49% | 15.95% | 10.02% | 9.21% | 9.6% | 12.42% | 13.99% | 14.44% |
| Earnings before Tax (EBT) 1 | 108.8 | 110.7 | 97.9 | 106.8 | 72.67 | 137.5 | 161.9 | 179.2 |
| Net income 1 | 73.68 | 72.96 | 68.9 | 73.41 | 45.92 | 88.6 | 108.7 | 120.9 |
| Net margin | 9.88% | 8.71% | 6.72% | 6.5% | 3.87% | 7.16% | 8.41% | 8.87% |
| EPS 2 | 1.490 | 1.400 | 1.300 | 1.400 | 0.8800 | 1.664 | 2.063 | 2.291 |
| Free Cash Flow 1 | 95.81 | 94.86 | 101.1 | 68.97 | 113 | 84.04 | 119 | 118.8 |
| FCF margin | 12.84% | 11.33% | 9.86% | 6.1% | 9.51% | 6.79% | 9.21% | 8.72% |
| FCF Conversion (EBITDA) | 53.83% | 45.39% | 47.38% | 31.88% | 49.18% | 30.5% | 40.03% | 37.55% |
| FCF Conversion (Net income) | 130.03% | 130.02% | 146.75% | 93.95% | 246.1% | 94.86% | 109.44% | 98.3% |
| Dividend per Share 2 | 0.5000 | 0.5000 | 0.5000 | 0.5000 | 1.000 | 0.7267 | 0.7544 | 0.7989 |
| Announcement Date | 2/5/20 | 2/4/21 | 3/10/22 | 2/9/23 | 2/7/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 279.2 | 251.6 | 265 | 285.4 | 327.7 | 290.8 | 304.2 | 595 | 285.7 | 306.9 | 284.6 |
| EBITDA 1 | 48.8 | 46.6 | 43.95 | 59.39 | 66.43 | 59.95 | 73.14 | 133.1 | 62.1 | 35.09 | 60.7 |
| EBIT 1 | 16.9 | 19.4 | 17.81 | 31.1 | 35.75 | 32.38 | 51.52 | - | 31.6 | -1.543 | 34.2 |
| Operating Margin | 6.05% | 7.71% | 6.72% | 10.9% | 10.91% | 11.13% | 16.94% | - | 11.06% | -0.5% | 12.02% |
| Earnings before Tax (EBT) | - | - | 18.19 | 43.36 | - | 20.88 | - | - | - | - | - |
| Net income | 12.4 | 18.2 | 12.07 | 29.34 | 13.8 | 14.38 | 31.49 | - | 16 | -15.9 | - |
| Net margin | 4.44% | 7.23% | 4.55% | 10.28% | 4.21% | 4.94% | 10.35% | - | 5.6% | -5.18% | - |
| EPS | 0.2800 | - | 0.2300 | 0.5600 | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/10/22 | 5/5/22 | 8/4/22 | 11/3/22 | 2/9/23 | 5/10/23 | 8/10/23 | 8/10/23 | 11/9/23 | 2/7/24 | 5/8/24 |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 440 | 480 | 628 | 691 | 703 | 659 | 580 | 495 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.472 x | 2.297 x | 2.944 x | 3.195 x | 3.058 x | 2.393 x | 1.953 x | 1.564 x |
| Free Cash Flow 1 | 95.8 | 94.9 | 101 | 69 | 113 | 84 | 119 | 119 |
| ROE (net income / shareholders' equity) | 28.3% | 21.9% | 16.5% | 14.7% | 16.1% | 15.4% | 16.6% | 17% |
| ROA (Net income/ Total Assets) | 7.69% | 7.5% | 6.15% | 5.04% | 5.6% | 5.07% | 5.88% | 6.43% |
| Assets 1 | 958.2 | 972.8 | 1,120 | 1,457 | 820.3 | 1,747 | 1,848 | 1,879 |
| Book Value Per Share 2 | 5.350 | 11.90 | 11.70 | 12.90 | 12.80 | 13.40 | 14.40 | 15.60 |
| Cash Flow per Share 2 | 2.240 | 2.900 | 3.120 | 2.770 | 3.440 | 2.750 | 3.370 | 3.660 |
| Capex 1 | 43.7 | 55.1 | 64.2 | 76.1 | 66.5 | 68.9 | 70.5 | 75.3 |
| Capex / Sales | 5.86% | 6.58% | 6.26% | 6.73% | 5.6% | 5.57% | 5.45% | 5.53% |
| Announcement Date | 2/5/20 | 2/4/21 | 3/10/22 | 2/9/23 | 2/7/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
27.52
EUR
Average target price
43.2
EUR
Spread / Average Target
+56.98%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -27.39% | 1.56B | |
| +16.58% | 338B | |
| +29.09% | 227B | |
| +4.53% | 152B | |
| +16.22% | 59.22B | |
| +18.95% | 34.22B | |
| +1.66% | 30.08B | |
| +166.75% | 29.88B | |
| +30.91% | 21.64B | |
| +39.43% | 14.13B |
- Stock Market
- Equities
- COP Stock
- Financials CompuGroup Medical SE & Co. KGaA
